Cybin Inc. Common Stock
HELP scores 11.8 on the Conservative profile, blending a fundamental score (80% weight, emphasizing quality and stability (84% of fundamental weight)) with a machine-learning signal (20% weight) trained on 82 features across 30 years of data.
Net penalties of -13.2 points significantly impact the ranking. Without these adjustments, HELP would rank considerably higher.
These features are direct inputs to the machine learning model. The model was trained on these signals alongside 100 features (including 12 momentum/technical indicators) to produce the ML percentile score.
| Stock | Score | P/E | Rev Growth | Margin | Mkt Cap |
|---|---|---|---|---|---|
| HELP | 11.8 | N/A | 0.0% | 0.0% | $340M |
| INCY | 89.9 | 15.8 | 21.2% | 25.0% | $20.2B |
| GMAB | 86.1 | 13.1 | 22.8% | 36.4% | $18.1B |
| CPRX | 83.7 | 13.7 | 23.5% | 37.6% | $2.9B |
| ASND | 78.3 | 16.6 | 98.0% | -31.7% | $14.0B |
| EXEL | 78.3 | 15.1 | 7.0% | 33.7% | $11.9B |
| VRTX | 78.2 | 32.1 | 8.9% | 32.9% | $125.2B |
| NBIX | 75.1 | 26.5 | 21.4% | 16.7% | $13.3B |
| RPRX | 75.0 | 25.1 | 5.1% | 32.4% | $19.8B |
| HOLX | 74.8 | 31.1 | 1.7% | 13.8% | $16.8B |
| AMGN | 74.2 | 26.0 | 10.0% | 21.0% | $210.2B |
| ARGX | 73.7 | 35.1 | 78.6% | 38.0% | $48.0B |
| REGN | 73.0 | 19.4 | 1.0% | 31.4% | $81.3B |
| ALKS | 72.9 | 16.5 | -6.4% | 23.9% | $5.0B |
| ISRG | 72.7 | 61.7 | 20.5% | 28.4% | $177.8B |
| KRYS | 71.5 | 41.4 | 473.0% | 30.7% | $8.0B |
| Sector Average | 36.6 | 41.9 | 161.5% | -3292.7% | โ |
Clinical-stage biopharmaceutical company developing psychedelic-based therapeutics including CYB003 (deuterated psilocybin analog) for major depressive disorder and CYB004 (deuterated DMT) for generalized anxiety disorder
Not enough price history to compute reliable entry and exit zones for this stock.
| Metric | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2025 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| Operating Income | $-57M | $-40M | $-34M | $-33M |
| Net Income | $-59M | $-47M | $-34M | $-31M |
| EPS (Diluted) | $-2.42 | $-1.94 | $-1.50 | $-1.46 |
| Gross Margin | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A |
Growth estimates have been dampened based on technical and fundamental signals. This is a post-hoc adjustment to prevent overly optimistic projections for stocks showing declining momentum or deteriorating fundamentals.
Scores are generated by a multi-stage ML pipeline combining fundamental analysis, ensemble predictions, and structural risk signals. All data is for research purposes only and does not constitute financial advice. Past performance does not guarantee future results.